Skip to main content
. Author manuscript; available in PMC: 2014 Feb 19.
Published in final edited form as: Mol Cancer Ther. 2012 Jul 23;11(10):2105–2115. doi: 10.1158/1535-7163.MCT-11-0873

Figure 4.

Figure 4

Analysis of sFRP1 expression and markers of apoptosis in ccRCC and TNBC cell lines treated with 1μM decitabine (5A2D) and 5nM romidepsin (Rom). (A) Protein lysates from treated A498, KIJ265T, MDA-231, and BT-20 cells were probed for PARP and caspase-3 cleavage identifying synergistic apoptotic escalation with combinatorial treatment. Accumulation of sFRP1 expression was observed with combination treatment. (B) Cell lines were examined for methylation status of the sFRP1 promoter and the ability of single and combinatorial drug treatments to modulate these methylation events via methylation specific PCR utilizing defined primers for the amplification of methylated or unmethylated sequences of sFRP1 (M=methylated, U= unmethylated).